MolNFT v1 · #149418 · protein
Lasb, hydroxymate inhibitor complex
6FZX · Keratinase KP2: “Lasb, hydroxymate inhibitor complex”. X-ray diffraction, 4 ligands (EEK, ZN, CA), 2 pockets (best druggability 0.51). MolNFT v1 #149418 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 6FZX
- Type
- protein
- Length
- 298 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Keratinase KP2
- UniProt
- E3ULB4
- Ligands
- EEK, ZN, CA, SO4
- Pockets
- 2 · best druggability 0.51
Structure
x-ray diffraction · 1 distinct chain · 41% helix, 16% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Keratinase KP2 | protein | 298 | 41% helix, 16% strand | E3ULB4 |
Ligands and binding sites
- EEK · ~{N}-(3,4-dichlorophenyl)-~{N}'-oxidanyl-propanediamide · ligand · chains A
- ZN · Zinc ion · metal · chains A
- CA · Calcium ion · metal · chains A
- SO4 · Sulfate ion · ion · chains A
- GOL · Glycerol · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 127 | 0.51 | 0.80 | 32 | EEK |
| 2 | 62 | 0.35 | 0.77 | 13 | empty |
Modifications
Observed in the structure: 2 disulfide (disulfide).
Compared structures
- 6FZX · LasB, hydroxymate Inhibitor Complex · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt E3ULB4
- Elsewhere: RCSB PDB 6FZX · PDBe 6FZX · UniProt E3ULB4
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.